1.Serum Levels of 8-Iso-Prostaglandin F2α and Raftlin in Patients with Generalized Anxiety Disorder
Onur HURSITOĞLU ; Ergül Belge KURUTAS
Clinical Psychopharmacology and Neuroscience 2023;21(2):370-376
Objective:
Although there are neurobiological studies of patients with generalized anxiety disorder (GAD), the topic is still open to research. Lipid peroxidation can generate new molecular signal sequences by altering protein amounts and activity. 8-Iso-Prostaglandin F2α (8-iso-PGF2α) is known to be an important lipid peroxidation marker. Raftlin, which is defined as a major lipid raft protein, is important for the regulation of signal transduction and inflammatory processes.
Methods:
Our aim in this study was to compare the 8-iso-PGF2α and Raftlin levels of forty patients diagnosed with GAD and 40 healthy controls (age-sex and body mass index-matched).
Results:
In the present study, increased serum 8-iso-PGF2α and Raftlin levels were found in patients with GAD compared to healthy controls.
Conclusion
To our knowledge, this is the first study to examine 8-iso-PGF2α and Raftlin levels in patients with GAD. These results expand our knowledge of oxidative stress and inflammatory processes in patients with GAD. Our study should be considered preliminary and further studies should be performed with larger sample groups comparing values before and after treatment.
2.Increased Serum G Protein-coupled Estrogen Receptor 1 Levels and Its Diagnostic Value in Drug Naïve Patients with Major Depressive Disorder.
Ebru FINDIKLI ; Ergül Belge KURUTAS ; Mehmet Akif CAMKURT ; Mehmet Fatih KARAASLAN ; Filiz IZCI ; Hüseyin Avni FINDIKLI ; Selçuk KARDAŞ ; Berat DAG ; Hatice ALTUN
Clinical Psychopharmacology and Neuroscience 2017;15(4):337-342
OBJECTIVE: The facts that depression is more prevalent in females than in males and females are exposed to depression more commonly during certain hormonal fluctuating periods indicate the role of sex hormones in physiopathology. Estrogen acts over estrogen receptors alpha and beta and recently identified G protein-coupled estrogen receptor 1 (GPER1). The present study aimed, for the first time, to evaluate serum GPER1 levels in drug-naïve major depressive disorder (MDD) patients. METHODS: The study included 56 newly diagnosed drug-naïve MDD patients aged between 18 and 50 years and 42 age- and gender-matched healthy volunteers. Medical history was obtained and physical examinations, laboratory tests, and the Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A) were performed. The serum GPER1 levels were measured. RESULTS: The HAM-D score was significantly higher in the MDD patients than in the controls. The GPER1 level was significantly higher in the MDD patients than in the controls. A positive correlation was found with GPER1 levels and depression scores. The receiver operating characteristic analysis revealed sensitivity, specificity, positive predictive value, and negative predictive value as 82.1%, 90.5%, 92.0%, and 79.2%, respectively, for the presence of depression, when the serum GPER1 value was ≥0.16. CONCLUSION: This study demonstrated significantly higher serum GPER1 levels in the MDD patients than in the controls, a positive correlation was found between GPER1 levels and depression scores and serum GPER1 level was valuable in predicting the presence of depression.
Anxiety
;
Depression
;
Depressive Disorder, Major*
;
Estrogen Receptor alpha*
;
Estrogens*
;
Female
;
Gonadal Steroid Hormones
;
Healthy Volunteers
;
Humans
;
Male
;
Physical Examination
;
ROC Curve
;
Sensitivity and Specificity